MARKET

DTIL

DTIL

Precision BioSciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.49
0.00
0.00%
Opening 10:21 12/02 EST
OPEN
11.32
PREV CLOSE
11.49
HIGH
11.59
LOW
11.24
VOLUME
121.43K
TURNOVER
--
52 WEEK HIGH
23.67
52 WEEK LOW
4.455
MARKET CAP
603.00M
P/E (TTM)
-3.8954
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020. This fireside chat has been pre-recorded and is now available for registered attendees via the Piper Sandler conference site until December 3. It is also available on Precision's website, www.PrecisionBiosciences.com in the Investors and Media section under Events and Presentations.About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.Investor Contact: Alex Kelly Chief Corporate Affairs Officer Alex.Kelly@precisionbiosciences.com
GlobeNewswire · 11/24 21:05
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
Eli Lilly, Precision BioSciences inks gene therapy pact
Eli Lilly (LLY) and Precision BioSciences (DTIL) have entered into a research and license agreement to utilize Precision's ARCUS genome editing platform for potential therapies for genetic disorders, with an
Seekingalpha · 11/20 12:17
Precision BioSciences up more than 20% after gene therapy pact with Eli Lilly
Eli Lilly (LLY) and Precision BioSciences (DTIL) have entered into a research and license agreement to utilize Precision's ARCUS genome editing platform for potential therapies for genetic disorders, with an
Seekingalpha · 11/20 12:17
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.
PR Newswire · 11/20 12:00
Precision BioSciences, Inc. (NASDAQ:DTIL) Just Reported, And Analysts Assigned A US$17.33 Price Target
A week ago, Precision BioSciences, Inc. (NASDAQ:DTIL) came out with a strong set of third-quarter numbers that could...
Simply Wall St. · 11/13 11:12
Precision BioSciences: Q3 Earnings Insights
Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which beat the estimate of ($0.66).Revenue of $7,363,000 up by 51.35% from the same period last year, which beat the estimate of $3,620,000.Looking Ahead Precision BioSciences hasn't issued any earnings guidance for the time being.View more earnings on DTILRevenue guidance hasn't been issued by the company for now.Technicals Company's 52-week high was at $23.67Company's 52-week low was at $4.46Price action over last quarter: Up 18.02%Company Description Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/10 12:28
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.Investor Contact: Alex Kelly Chief Corporate Affairs Officer Alex.Kelly@precisionbiosciences.com
GlobeNewswire · 11/03 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DTIL. Analyze the recent business situations of Precision BioSciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DTIL stock price target is 17.71 with a high estimate of 25.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 164
Institutional Holdings: 28.47M
% Owned: 54.25%
Shares Outstanding: 52.48M
TypeInstitutionsShares
Increased
42
2.76M
New
36
-11.54K
Decreased
23
2.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.25%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
President/Chief Executive Officer/Director
Matthew Kane
Chief Financial Officer
Abid Ansari
Corporate Executive
Fayaz Khazi
Chief Operating Officer
David Thomson
Chief Scientific Officer/Director
Derek Jantz
General Counsel/Secretary
Dario Scimeca
Other
Christopher Heery
Other
Alex Kelly
Independent Director
Kevin Buehler
Independent Director
Geno Germano
Independent Director
Raymond Schinazi
Independent Director
Shalini Sharp
Independent Director
Tony Yao
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DTIL
Precision BioSciences, Inc. is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s four product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, PBCAR269A and PBCAR371A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Precision BioSciences Inc stock information, including NASDAQ:DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.